GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction
Nature Reviews Gastroenterology & Hepatology · 2024
DOI: 10.1038/s41575-024-00977-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nature Reviews Gastroenterology & Hepatology, 2024. Verfasst von Jonathan Goldney und 1 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, UK. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Hypoglycemic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, UK.
- NIHR Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK.
- Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, UK. melanie.davies@uhl-tr.nhs.uk.
- NIHR Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. melanie.davies@uhl-tr.nhs.uk.
Zitieren
APA
Goldney, J., & Davies, M. J. (2024). GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-024-00977-2
Vancouver
Goldney J, Davies MJ. GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction. Nature Reviews Gastroenterology & Hepatology. 2024. doi:10.1038/s41575-024-00977-2
BibTeX
@article{Goldney2024,
author = {Goldney, Jonathan and Davies, Melanie J},
title = {GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction},
journal = {Nature Reviews Gastroenterology & Hepatology},
year = {2024},
doi = {10.1038/s41575-024-00977-2}
}
EUVIMED